Back to Newsroom
Back to Newsroom

SHAREHOLDER ALERT: RLX ARDX ATVI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Tuesday, 03 August 2021 06:45 PM

The Law Offices of Vincent Wong

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / August 3, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

RLX Technology Inc. (NYSE:RLX)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/rlx-technology-inc-loss-submission-form?prid=18208&wire=1
Lead Plaintiff Deadline: August 9, 2021
This lawsuit is on behalf of persons who purchased, or otherwise acquired, RLX American Depository Shares pursuant or traceable to the documents issued in connection with RLX's January 2021 initial public stock offering.

Allegations against RLX include that: the Company's then-existing exposure to China's ongoing campaign to establish a national standard for e-cigarettes, which would bring them into line with ordinary cigarette regulations, and that RLX's reported financials were not nearly as robust as the offering materials projected, nor were they indicative of future results. As a result, investors purchased RLX shares at artificially inflated prices.

Ardelyx Inc. (NASDAQ:ARDX)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/ardelyx-inc-loss-submission-form?prid=18208&wire=1
Lead Plaintiff Deadline: September 28, 2021
Class Period: August 6, 2020 - July 19, 2021

Allegations against ARDX include that: the likelihood that tenapanor would be approved by the Food and Drug Administration ("FDA"). Defendants possessed, were in control over, and as a result, knew that the data submitted to support the New Drug Application was insufficient in that it showed a lack of clinical relevance of the drug's treatment effect, making it foreseeably likely that the FDA would not approve the drug.

Activision Blizzard, Inc. (NASDAQ:ATVI)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/activision-blizzard-inc-loss-submission-form-2?prid=18208&wire=1
Lead Plaintiff Deadline: October 4, 2021
Class Period: August 4, 2016 - July 27, 2021

Allegations against ATVI include that: (1) Activision Blizzard discriminated against women and minority employees; (2) Activision Blizzard fostered a pervasive "frat boy" workplace culture that
continues to thrive; (3) numerous complaints about unlawful harassment,
discrimination, and retaliation were made to human resources personnel and executives which went unaddressed; (4) the pervasive culture of harassment, discrimination, and retaliation would result in serious impairments to Activision Blizzard's operations; (5) as a result of the foregoing, the Company was at greater risk of regulatory and legal scrutiny and enforcement, including that which would have a material adverse effect; (6) Activision Blizzard failed to inform shareholders that the California Department of Fair Employment and Housing had been investigating Activision Blizzard for harassment and discrimination; and (7) as a result, Defendants' statements about Activision Blizzard's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
 

The Law Offices of Vincent Wong, Tuesday, August 3, 2021, Press release picture

To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]

SOURCE: The Law Offices of Vincent Wong

Topic:
Lawsuits
Back to newsroom
Back to Newsroom

Contact Us Today


If you have questions or want to learn more about our products, our team’s here to help!

Share by: